PD-1

[BriaCell Therapeutics, Corp.] BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announced the open recruitment and enrollment of their collaborative clinical study with Incyte for the treatment of advanced breast cancer.

[Communications Biology] Investigators demonstrated that profiling functional proteins involved in cell-to-cell interactions in the microenvironment could predict recurrence and overall survival.

[Cancer Immunology, Immunotherapy] To determine the immune-modulatory influence of CSC in small cell lung cancer (SCLC), scientists focused on the characterization of CD44+CD90+ CSC-like subpopulations in SCLC.

[Cell Death & Differentiation] When comparing nasopharyngeal swabs from cancer and noncancer patients for RT-qPCR cycle thresholds measuring acute respiratory SARS-CoV-2 in 1063 patients, researchers found that malignant disease favored the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies.

[Journal of Cancer Research and Clinical Oncology] The effect of combined PD-1/PD-L1 and extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor treatment was investigated of cell growth and intracellular impact of breast cancer cell lines.

[BMC Cancer] The authors investigated the prognostic role of AFP and PIVKA-II in hepatocellular carcinoma patients receiving anti-PD-1 immunotherapy.